Reversal for acquired resistance to EGFR inhibitors in lung cancer
10.3760/cma.j.issn.1673-422X.2013.11.013
- VernacularTitle:肺癌表皮生长因子受体酪氨酸激酶抑制剂获得性耐药的逆转
- Author:
Chenchen LI
;
Jifeng FENG
- Publication Type:Journal Article
- Keywords:
Lung neoplasms;
Receptor,epidermal growth factor;
Drug resistance;
Inhibitors
- From:
Journal of International Oncology
2013;40(11):843-846
- CountryChina
- Language:Chinese
-
Abstract:
Epidermal growth factor receptor (EGFR) inhibitors targeted therapy is the forward position means for non-small cell lung cancer.However,acquired resistance to EGFR inhibitors limits the development of targeted drugs.Using existing data on drug resistance in EGFR-mutant lung cancer,this review discusses three basic approaches for overcoming resistance to EGFR-targeted therapies:intensification of EGFR inhibition,combination of EGFR inhibitors with other targeted therapies,and altering clinical management via alternate pathways.
